A clinical study to investigate the safety, tolerability and pharmacokinetic profile of single ascending concentrations of OPT101 in peritoneal dialysis patients.

2025-522966-61-00 Protocol OPT-001 Human pharmacology (Phase I) - First administration to humans Ongoing, recruitment ended

Start 16 Feb 2026 · Status Ongoing, recruitment ended · 1 EU/EEA countries · 1 sites · Protocol OPT-001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruitment ended
Participants planned 12
Countries 1
Sites 1

Chronic kidney disease

Key facts

Sponsor
OPTERION Health AG
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Not possible to specify
Trial duration
16 Feb 2026 → ongoing
Decision date (initial)
2026-01-09
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Chronic kidney disease

VersionLevelCodeTermSystem organ class
28.0 LLT 10076411 Chronic kidney disease stage 4 10038359
28.0 LLT 10076412 Chronic kidney disease stage 5 10038359

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

OPTERION Health AG

Sponsor organisation
OPTERION Health AG
Address
Hofackerstrasse 40b
City
Muttenz
Postcode
4132
Country
Switzerland

Scientific contact point

Organisation
OPTERION Health AG
Contact name
Maxim Voropaiev

Public contact point

Organisation
OPTERION Health AG
Contact name
Maxim Voropaiev

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Latvia Ongoing, recruitment ended 12 1
Rest of world 0

Investigational sites

Latvia

1 site · Ongoing, recruitment ended
Pauls Stradins Clinical University Hospital
NEPHROLOGY CENTRE, Pilsonu Iela 13, 1002, Riga

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Latvia 2026-02-16 2026-02-23 2026-05-18

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-09-10 Latvia Acceptable
2026-01-07
2026-01-09